TORONTO, Sept. 23 /CNW/ - Microbix Biosystems Inc. (MBX:TSX) today announced that it will be collaborating with a third-party to test the Company's yield enhancement technology in the production of influenza vaccine including avian influenza. As well, Microbix intends to build on the positive data for this technology, developed during recent corporate collaborations, by seeking independent, non-commercial validation. The patent protection strategy is moving through the process on schedule in several countries including the US Patent Office. The Company also expects to announce, in the next few weeks, developments toward possible agreements regarding two other products in its pipeline. "We've had a solid year of growth in our core business, and this has allowed us to move aggressively forward with our strategy," said William Gastle, President and CEO of Microbix. "Since conception, MBX has always used its profits for research and development of value-creating products. Management believes that shareholders will ultimately benefit from these activities as the Company brings new products and technologies into the marketplace." "Our business model continues to produce strong financial results and new opportunities for market growth," said Gastle. This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. For instance, product negotiations may proceed slowly or not at all and may not result in agreements acceptable to the Company or at all, or the Company may be unable to obtain independent non-commercial validation. These forward- looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. %SEDAR: 00004220E
Published Sep 23 2005
3 min read